Efficacy and Safety of Tirzepatide in Overweight and Obese Adult Patients with Type 1 Diabetes
Authors' conclusion
In this pilot (off label) study, we conclude that tirzepatide facilitated an average 18.5% weight loss (>46 pounds) and improved glucose control in OW/OB patients with T1D at 1 year.
Study context
- Population
- Overweight or obese adults with T1D, followed for 1 year; 62 of 184 prescribed tirzepatide met inclusion criteria
- Participants
- 62 vs 37
- Exposure
- Tirzepatide vs no weight-loss medication
- Treatedn = 62
- Controln = 37reference
- Outcome
- BMI and weight
- Follow-up
- All time points to 1 year
Methodological detailssingle-centre, real-world, frequency matched controls, pilot (off label), Mean (±SD) weekly tirzepatide dose 5.6 ± 1.9 mg at 3 months, 9.7 ± 3.3 mg at 1 year
- Single-centre
- Real-world
- Frequency matched controls
- Pilot (off label)
- Mean (±SD) weekly tirzepatide dose 5.6 ± 1.9 mg at 3 months, 9.7 ± 3.3 mg at 1 year
Main finding
As reported in the abstract
- Significantly larger declines in body mass index (BMI) and weight with treated vs controls across all time points (among those with data available)
Observational data: associations, not effects.
Further findings
- HbA1c change in treated · 1 year
- −0.67%
HbA1c change in treated · 1 year
- HbA1c decreased in treated as early as 3 months, sustained through 1 year
Insulin dose
- Insulin dose decreased at 3 months and throughout the study period
CGM metrics
- Mean glucose, TIR, TAR, SD and CV significantly improved in treated
Safety
- Hospitalizations from severe hypoglycemia or DKA
- 0
Original publication
Efficacy and Safety of Tirzepatide in Overweight and Obese Adult Patients with Type 1 Diabetes. Diabetes Technol Ther. Published 18 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →